UPSC TO BEGIN INTERVIEWS FOR CIVIL SERVICES EXAM FROM AUG 2

The Union Public Service Commission (UPSC) has decided to commence interviews for civil services examination 2020, which were deferred due to a surge in COVID-19 cases, from August 2, according to an official statement.

The civil services examination is conducted annually by the UPSC in three stages -- preliminary, main and personality test (interview) -- to select officers of the Indian Administrative Service (IAS), Indian Foreign Service (IFS) and the Indian Police Service (IPS), among others. It had in April this year deferred interviews for the prestigious examination due to increase in coronavirus cases.

“After reviewing the situation, the Commission has decided to commence the personality test of the civil services examination, 2020 from 02.08.2021,” according to the statement issued by the UPSC.

The e-summon letters of personality tests (Interviews) of the candidates will be made available shortly, which may be downloaded from the Commission’s website, it said. “No request for change in the date and time of the personality test (interview) intimated to the candidates will ordinarily be entertained,” the Commission said.

On the basis of the results of the civil services (main) examination, 2020 declared by the UPSC on March 23 this year, the Commission decided to commence the personality tests (interviews) of the civil services (main) examination, 2020 from April 26.

In 2020, we transferred to Biological E the seed stock to produce this recombinant protein Covid-19 vaccine candidate. Biological E have been doing a number of things since: they are advancing the manufacturing, and are also maturing the process and scaling it up. They are testing the manufacturing stock, and at the same time, have engaged in a clinical development plan. The company has got the approval to initiate large Phase 2/3 trials in India, while in parallel, it’s also working with global agencies, including CEPI (Coalition for Epidemic Preparedness Innovations) to launch

Yes, in our laboratories, working in partnership with Biological E, we have evaluated the performance of the vaccine using our pseudovirus technique, and clearly, the vaccine induces cross neutralising antibodies against the different variants, including B.1.617 (Delta) variant. We are also re-engineer

That is a hard choice because we know that you really require the two-dose scheme to ensure